🔎 Trials Near Me

Главная › Острый миелоидный лейкоз › Нью-Джерси

Клинические исследования Острый миелоидный лейкоз в штате Нью-Джерси

32 исследований по теме Острый миелоидный лейкоз ищут участников в центрах в штате Нью-Джерси.

Города в штате Нью-Джерси

Официальный текст исследования (на английском)

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooper Hospital University Medical Center, Camden
  • Cooperman Barnabas Medical Center, Livingston
  • и еще 7
Набор участниковФаза 2
Возраст от 18 лет · Любой пол · Обновлено 5 окт. 2026 г. · NCT05564390

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Englewood Hospital and Medical Center, Englewood
  • Hackettstown Medical Center, Hackettstown
  • Morristown Medical Center, Morristown
  • и еще 6
Набор участниковНаблюдательное исследованиеПриглашаются здоровые добровольцы
Возраст от 40 до 75 · Любой пол · Обновлено 2 окт. 2026 г. · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Memorial Sloan Kettering Monmouth, Middletown
  • Memorial Sloan Kettering Bergen, Montvale
  • и еще 1
Набор участниковФаза 1
Возраст от 18 лет · Любой пол · Обновлено 1 окт. 2026 г. · NCT06484062

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Набор участниковФаза 1
Возраст от 12 до 78 · Любой пол · Обновлено 29 сент. 2026 г. · NCT03802695

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooperman Barnabas Medical Center, Livingston
  • Monmouth Medical Center, Long Branch
  • и еще 6
Набор участниковФаза 2
Возраст от 18 до 59 · Любой пол · Обновлено 28 сент. 2026 г. · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Набор участниковФаза 3
Возраст от 18 лет · Любой пол · Обновлено 25 сент. 2026 г. · NCT06852222

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooperman Barnabas Medical Center, Livingston
  • Monmouth Medical Center, Long Branch
  • и еще 4
Набор участниковФаза 2
Возраст от 18 лет · Любой пол · Обновлено 22 сент. 2026 г. · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooper Hospital University Medical Center, Camden
  • Cooperman Barnabas Medical Center, Livingston
  • и еще 7
Набор участниковФаза 2
Возраст от 18 до 59 · Любой пол · Обновлено 22 сент. 2026 г. · NCT05554406

A Study of CRD3874-SI in People With Leukemia

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (All protocol activities), Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
Набор участниковФаза 1
Возраст от 18 лет · Любой пол · Обновлено 22 сент. 2026 г. · NCT07661095

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Cooperman Barnabas Medical Center, Livingston
  • Monmouth Medical Center, Long Branch
  • и еще 6
Набор участниковФаза 2
Возраст от 18 лет · Любой пол · Обновлено 22 сент. 2026 г. · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Hackensack University Medical Center, Hackensack
  • Morristown Medical Center, Morristown
  • Jersey Shore Medical Center, Neptune City
  • и еще 4
Набор участниковФаза 3
6 Months – 21 Years · Любой пол · Обновлено 17 сент. 2026 г. · NCT04293562

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • John Theurer Cancer Center at Hackensack UMC, Hackensack
Набор участниковФаза 2
Возраст от 18 лет · Любой пол · Обновлено 16 сент. 2026 г. · NCT06824168

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • Atlantic Health, Morristown
Набор участниковФаза 1/2
Возраст от 12 лет · Любой пол · Обновлено 3 сент. 2026 г. · NCT04588922

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Hackensack University Medical Center, Hackensack
  • Morristown Medical Center, Morristown
  • Jersey Shore Medical Center, Neptune City
  • и еще 3
Набор участниковФаза 1/2
До 22 лет · Любой пол · Обновлено 25 авг. 2026 г. · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Hackensack University Medical Center, HMH, Hackensack
  • Morristown Medical Center, Morristown
Набор участниковФаза 3
29 Days – 21 Years · Любой пол · Обновлено 24 авг. 2026 г. · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • Rutgers Biomedical and Health Sciences, New Brunswick
Набор участниковФаза 3
Возраст от 18 лет · Любой пол · Обновлено 20 авг. 2026 г. · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Набор участниковФаза 1
Возраст от 18 лет · Любой пол · Обновлено 20 авг. 2026 г. · NCT06001788

A Pilot Study of Soursop Tea in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Multiple Myeloma (MM)

  • MDA at Cooper University Health Care, Camden
Набор участниковРанняя фаза 1
Возраст от 18 лет · Любой пол · Обновлено 18 авг. 2026 г. · NCT07771803

L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML

  • Atlantic Health, Morristown
Набор участниковФаза 2/3
Возраст от 18 до 80 · Любой пол · Обновлено 5 авг. 2026 г. · NCT06788756

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

  • Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Набор участниковФаза 2
Возраст от 60 лет · Любой пол · Обновлено 17 июл. 2026 г. · NCT07392242

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Набор участниковФаза 2
Возраст от 18 лет · Любой пол · Обновлено 7 июл. 2026 г. · NCT07216443

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Hackensack University Medical Center, Hackensack
  • Robert Wood Johnson/Cancer Institute of New Jersey, New Brunswick
Набор участниковНаблюдательное исследование
Любой возраст · Любой пол · Обновлено 6 июл. 2026 г. · NCT01351545

A Study of Revumenib and Mezigdomide in People With Leukemia

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
Набор участниковФаза 1/2
Возраст от 12 лет · Любой пол · Обновлено 22 июн. 2026 г. · NCT07356154

A Study of CD371-YSNVZIL-18 CAR T Cells in People With Acute Myeloid Leukemia

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Набор участниковФаза 1
Возраст от 1 лет · Любой пол · Обновлено 22 июн. 2026 г. · NCT06017258

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

  • Memorial Sloan Kettering Basking Ridge, Basking Ridge
  • Memorial Sloan Kettering Monmouth, Middletown
  • Memorial Sloan Kettering Bergen, Montvale
Набор участниковФаза 1
Возраст от 18 лет · Любой пол · Обновлено 22 июн. 2026 г. · NCT05756777

A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited protocol activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Набор участниковФаза 1
Возраст от 18 до 70 · Любой пол · Обновлено 17 июн. 2026 г. · NCT07011004

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

  • John Theurer Cancer Center / Hackensack University, Hackensack
Набор участниковФаза 2/3
Возраст от 18 лет · Любой пол · Обновлено 30 апр. 2026 г. · NCT04256317

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Atlantic Health, Morristown
  • Rutgers Cancer Institute of New Jersey, New Brunswick
Набор участниковФаза 1/2
Возраст от 12 лет · Любой пол · Обновлено 24 мар. 2026 г. · NCT04988555

Phase IB/II of CPX-351 for Relapse Prevention in AML

  • John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Набор участниковФаза 1/2
Возраст от 18 лет · Любой пол · Обновлено 23 мар. 2026 г. · NCT04990102

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • Hackensack University Medical Center, Hackensack
  • Rutgers Cancer Institute, New Brunswick
Набор участниковФаза 1
Возраст от 18 лет · Любой пол · Обновлено 13 мар. 2026 г. · NCT05735184

A Study of ADCLEC.syn1 in People With Acute Myeloid Leukemia

  • Memorial Sloan Kettering at Basking Ridge (Limited Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale
Набор участниковФаза 1
Возраст от 18 лет · Любой пол · Обновлено 10 мар. 2026 г. · NCT05748197

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

  • Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale
Набор участниковФаза 2
Возраст от 18 лет · Любой пол · Обновлено 24 февр. 2026 г. · NCT06773208

Источник: ClinicalTrials.gov, данные получены 6 окт. 2026 г.. Каждая исследование устанавливает свои критерии участия; решение о включении принимает исследовательская группа.